Pharmacopsychiatry 2010; 43(2): 73-80
DOI: 10.1055/s-0029-1239592
Original Paper

© Georg Thieme Verlag KG Stuttgart · New York

Does Oral Antipsychotic Pre-Treatment Influence Outcome of a Switch to Long-Acting Injectable Risperidone in Patients with Schizophrenia?

M. Schmauß1 , B. Diekamp2 , M. Gerwe2 , A. Schreiner2 , B. Ibach2
  • 1Department of Psychiatry, Bezirkskrankenhaus Augsburg, Germany
  • 2Medical and Scientific Affairs, Janssen Cilag GmbH, Neuss, Germany
Further Information

Publication History

received 06.04.2009 revised 24.08.2009

accepted 24.08.2009

Publication Date:
03 February 2010 (online)

Abstract

Introduction: The objective of this open-label study was to evaluate treatment benefits of risperidone long-acting injectable (RLAI) in patients with schizophrenia following direct transition from oral risperidone (RIS) compared with transition from other oral second generation antipsychotics.

Methods: Stable in- or outpatients (n=206) receiving RIS or OQAZ (olanzapine, quetiapine, amisulpride, ziprasidone) were transitioned to RLAI for 12 weeks. The primary outcome was the between-group treatment difference in change in PANSS total score from baseline to endpoint. Secondary outcomes included health-related quality-of-life and therapeutic alliance.

Results: Mean between-group difference in the change in PANSS total score from baseline to endpoint was −6.1 (CI: −17.6, 5.4), suggesting greater improvement in OQAZ than RIS patients. Due to the pre-specified non-inferiority margin of 5.1, it could not be concluded that OQAZ pre-treatment results in an at least non-inferior PANSS reduction versus RIS pre-treatment. Patient satisfaction with medication and change in quality-of-life subscores showed advantages for OQAZ patients.

Discussion: Compared to RIS pre-treatment, clinically stable patients with schizophrenia who are pre-treated with OQAZ might draw a stronger clinical benefit from direct transition to RLAI.

References

Correspondence

PD Dr. Bernd Ibach

Leitender Arzt

Alterspsychiatrie/-Psychotherapie

Psychiatrische Dienste Thurgau

Postfach 154

8596 Münsterlingen

Switzerland

Phone: 0041-(0)71-686-4206

Email: bernd.ibach@stgag.ch